Studien

Urologische Tumoren

CA209-274

STRONG

  • Status: aktiv, NCT03084471
  • An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract
  • Kurzinformation
  • Ansprechpartner:
    Dr. Schleicher
    Telefon: 0711 278-35622
    E-Mail: j.schleicher@klinikum-stuttgart.de
  • Studienzentrale
    Telefon: 0711 278-30410, -30411, -30414
    E-Mail: scc-studienzentrale@klinikum-stuttgart.de

PCO-Studie